Endocrine System

Register for your FREE account now and join the thousands of healthcare professionals who have depended on us for over 26 years for accurate, concise, and timely drug information.

Email*

Password*

Keep me logged in Forgot your password?

Email*

Endocrine System Resource Center

Welcome to the MPR Endocrine System Resource Center, where you will find everything you need to make informed clinical decisions.

Drug Monographs

Click on the subcategory below to find drug monographs for that particular area.

News

Causality Link Between HDL Cholesterol, MI Challenged

Genetic mechanisms that are associated with high plasma levels of high-density lipoprotein (HDL) cholesterol do not reduce the risk of myocardial infarction (MI), adding question to causality of link.

Statins Benefit Those at Low Risk for Vascular Events

Reduction of low-density lipoprotein (LDL) cholesterol with statins is associated with a decrease in major vascular events, even for individuals with a five-year risk of <10%.

Retinal Vessel Diameter Linked to Heart Disease, Hypertension

Baseline retinal vessel diameter is an independent predictor of incident hypertension, lower extremity arterial disease (LEAD), and any cardiovascular disease (CVD) at six years in African-American patients with type 1 diabetes mellitus.

Screening for Retinopathy Every Two Years Deemed Safe

For patients with type 2 diabetes without evidence of retinopathy, increasing the screening interval to every two years yields no increased risk of retinopathy-mediated vision loss and reduces screening costs.

ECO: Behavioral Treatment for Obesity Effective in Children

Behavioral treatment for obesity is much more effective for younger children than for adolescents.

JENTADUETO

3/12/2012

Boehringer Ingelheim and Lilly

Pharmacological Class: Dipeptidyl peptidase-4 inhibitor (DPP-4) + biguanide.

Active Ingredient(s): Linagliptin, metformin HCl; 2.5mg/500mg, 2.5mg/850mg, 2.5mg/1000mg; tablets.

Indication: Adjunct to diet and exercise in type 2 diabetes when treatment with both linagliptin and metformin is appropriate.

BYDUREON

2/27/2012

Amylin and Alkermes

Pharmacological Class: Antidiabetic (glucagon-like peptide-1 [GLP-1] receptor agonist).

Active Ingredient(s): Exenatide extended-release 2mg; pwd for SC inj after reconstitution.

Indication: As adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes. Not for first-line therapy in patients inadequately controlled on diet and exercise.